Remy Cassady, Shubrook Jay H, Nakazawa Masato, Drozek David
J Am Osteopath Assoc. 2017 May 1;117(5):293-300. doi: 10.7556/jaoa.2017.054.
Previous studies of the Complete Health Improvement Program (CHIP) have demonstrated short-term improvements in select metabolic and cardiovascular biomarkers in community-based programs. However, less is known about the benefits of an employer-funded lifestyle intervention program.
To determine if participation in employer-provided CHIP would result in improvements in short-term metabolic and cardiovascular biomarkers, and to compare the results of the current study to a larger national study.
This observational study evaluated metabolic and cardiovascular biomarker changes in employer health insurance beneficiaries enrolled in CHIP between August 2012 and November 2014. Body mass index; blood pressure (systolic and diastolic); total cholesterol, low-density lipoprotein, high-density lipoprotein, fasting plasma glucose, and triglyceride levels; and weight were measured at baseline and after CHIP.
Of 160 employees enrolled in CHIP, 115 women and 45 men agreed to participate in the study. Overall, the participants demonstrated significant reductions in body mass index, from a baseline average of 31.5 to a post-CHIP average of 30.5 (P<.001), systolic blood pressure from 124.5 to 119.4 mm Hg (P=.017), diastolic blood pressure from 77.3 to 74.5 mm Hg (P=.046), total cholesterol from 186.0 to 168.8 mg/dL (P<.001), low-density lipoprotein from 112.9 to 99.3 mg/dL (P<.001), high-density lipoprotein from 48.8 to 46.4 mg/dL (P<.001), and fasting plasma glucose from 100.8 to 96.5 mg/dL (P<.001).
When funded by an employer, CHIP demonstrated short-term improvements in select metabolic and cardiovascular biomarkers. Future studies will analyze these data to determine whether these findings translate into subsequent decreased employee absenteeism and reduced beneficiary health claims.
先前对完全健康改善计划（CHIP）的研究表明，在社区项目中，某些代谢和心血管生物标志物有短期改善。然而，对于雇主资助的生活方式干预计划的益处了解较少。
确定参与雇主提供的CHIP是否会导致短期代谢和心血管生物标志物的改善，并将本研究结果与一项更大规模的全国性研究结果进行比较。
这项观察性研究评估了2012年8月至2014年11月期间参加CHIP的雇主医疗保险受益人的代谢和心血管生物标志物变化。测量了体重指数、血压（收缩压和舒张压）、总胆固醇、低密度脂蛋白、高密度脂蛋白、空腹血糖和甘油三酯水平，以及基线时和参加CHIP后的体重。
在160名参加CHIP的员工中，115名女性和45名男性同意参与研究。总体而言，参与者的体重指数显著降低，从基线时的平均31.5降至参加CHIP后的平均30.5（P<0.001）；收缩压从124.5降至119.4毫米汞柱（P=0.017）；舒张压从77.3降至74.5毫米汞柱（P=0.046）；总胆固醇从186.0降至168.8毫克/分升（P<0.001）；低密度脂蛋白从112.9降至99.3毫克/分升（P<0.001）；高密度脂蛋白从48.8降至46.4毫克/分升（P<0.001）；空腹血糖从100.8降至96.5毫克/分升（P<0.001）。
当由雇主资助时，CHIP在某些代谢和心血管生物标志物方面显示出短期改善。未来的研究将分析这些数据，以确定这些发现是否会转化为随后员工旷工率的降低和受益人的健康索赔减少。
